Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19
Status:
Active, not recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the superiority of Polyoxidonium®, lyophilizate
for solution for injections and topical application, 6 mg over placebo in hospitalized
patients with coronavirus disease (COVID-19). This is a multicentre prospective, randomized,
double-blind, placebo-controlled, parallel-group phase IIb\IIIa clinical trial.